Organicell Regenerative Medicine, Inc. Logo

Organicell Regenerative Medicine, Inc.

OCEL

(1.8)
Stock Price

2,74 USD

-257.91% ROA

1664.76% ROE

-2.78x PER

Market Cap.

19.974.944,00 USD

-55.85% DER

0% Yield

-157.42% NPM

Organicell Regenerative Medicine, Inc. Stock Analysis

Organicell Regenerative Medicine, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Organicell Regenerative Medicine, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (-9.6x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (-78%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

4 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

5 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

6 ROE

Negative ROE (-2545%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

7 ROA

The stock's ROA (-364.16%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Organicell Regenerative Medicine, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Organicell Regenerative Medicine, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Organicell Regenerative Medicine, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Organicell Regenerative Medicine, Inc. Revenue
Year Revenue Growth
2011 18.079
2012 87.149 79.26%
2013 82.968 -5.04%
2014 49.198 -68.64%
2015 147.629 66.67%
2016 184.881 20.15%
2017 569.845 67.56%
2018 964.530 40.92%
2019 1.702.271 43.34%
2020 3.055.776 44.29%
2021 5.597.487 45.41%
2022 6.491.008 13.77%
2023 5.687.536 -14.13%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Organicell Regenerative Medicine, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 54.863 100%
2020 233.526 76.51%
2021 1.120.067 79.15%
2022 791.326 -41.54%
2023 -60.000 1418.88%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Organicell Regenerative Medicine, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 18.811
2012 38.373 50.98%
2013 70.703 45.73%
2014 94.956 25.54%
2015 861.099 88.97%
2016 1.133.796 24.05%
2017 9.050.743 87.47%
2018 4.245.349 -113.19%
2019 3.177.924 -33.59%
2020 15.095.111 78.95%
2021 17.793.709 15.17%
2022 14.580.434 -22.04%
2023 10.082.276 -44.61%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Organicell Regenerative Medicine, Inc. EBITDA
Year EBITDA Growth
2011 -11.725
2012 -12.339 4.98%
2013 -32.175 61.65%
2014 -65.817 51.11%
2015 -762.795 91.37%
2016 -1.042.972 26.86%
2017 -8.613.159 87.89%
2018 -3.460.858 -148.87%
2019 -1.676.905 -106.38%
2020 -12.368.449 86.44%
2021 -12.665.924 2.35%
2022 -8.165.789 -55.11%
2023 -3.937.936 -107.36%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Organicell Regenerative Medicine, Inc. Gross Profit
Year Gross Profit Growth
2011 7.086
2012 26.034 72.78%
2013 38.528 32.43%
2014 29.139 -32.22%
2015 98.218 70.33%
2016 90.479 -8.55%
2017 409.219 77.89%
2018 755.232 45.82%
2019 1.401.434 46.11%
2020 2.657.170 47.26%
2021 5.049.606 47.38%
2022 5.737.474 11.99%
2023 5.155.900 -11.28%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Organicell Regenerative Medicine, Inc. Net Profit
Year Net Profit Growth
2011 -11.725
2012 -12.339 4.98%
2013 -32.175 61.65%
2014 -65.817 51.11%
2015 -738.354 91.09%
2016 -1.253.201 41.08%
2017 -8.972.132 86.03%
2018 -3.462.158 -159.15%
2019 -1.868.712 -85.27%
2020 -12.793.428 85.39%
2021 -12.819.971 0.21%
2022 -8.950.154 -43.24%
2023 -4.364.020 -105.09%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Organicell Regenerative Medicine, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 0
2012 0 0%
2013 0 0%
2014 -2 100%
2015 -2 0%
2016 -2 0%
2017 -16 87.5%
2018 -3 -700%
2019 -1 0%
2020 -4 100%
2021 -2 -50%
2022 -2 -100%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Organicell Regenerative Medicine, Inc. Free Cashflow
Year Free Cashflow Growth
2011 -12.926
2012 -8.748 -47.76%
2013 -29.951 70.79%
2014 -64.738 53.74%
2015 -392.695 83.51%
2016 -574.501 31.65%
2017 -926.663 38%
2018 -516.567 -79.39%
2019 -598.190 13.64%
2020 -1.951.193 69.34%
2021 -3.105.096 37.16%
2022 -3.990.583 22.19%
2023 214.717 1958.53%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Organicell Regenerative Medicine, Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 -12.926
2012 -8.748 -47.76%
2013 -29.951 70.79%
2014 -64.738 53.74%
2015 -384.791 83.18%
2016 -548.188 29.81%
2017 -881.527 37.81%
2018 -511.998 -72.17%
2019 -565.454 9.45%
2020 -1.812.499 68.8%
2021 -2.609.085 30.53%
2022 -3.165.840 17.59%
2023 220.453 1536.06%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Organicell Regenerative Medicine, Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 7.904 100%
2016 26.313 69.96%
2017 45.136 41.7%
2018 4.569 -887.87%
2019 32.736 86.04%
2020 138.694 76.4%
2021 496.011 72.04%
2022 824.743 39.86%
2023 5.736 -14278.36%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Organicell Regenerative Medicine, Inc. Equity
Year Equity Growth
2011 13.275
2012 -61 21862.3%
2013 11.334 100.54%
2014 -52.261 121.69%
2015 12.848 506.76%
2016 -783.074 101.64%
2017 -3.556.957 77.98%
2018 -1.214.826 -192.8%
2019 -1.562.549 22.25%
2020 -1.391.816 -12.27%
2021 -2.665.593 47.79%
2022 1.888.604 241.14%
2023 -1.241.019 252.18%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Organicell Regenerative Medicine, Inc. Assets
Year Assets Growth
2011 20.760
2012 18.563 -11.84%
2013 32.479 42.85%
2014 10.937 -196.96%
2015 152.597 92.83%
2016 69.898 -118.31%
2017 376.780 81.45%
2018 117.040 -221.92%
2019 626.260 81.31%
2020 1.334.172 53.06%
2021 1.932.957 30.98%
2022 6.200.688 68.83%
2023 2.782.200 -122.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Organicell Regenerative Medicine, Inc. Liabilities
Year Liabilities Growth
2011 7.485
2012 18.624 59.81%
2013 21.145 11.92%
2014 63.198 66.54%
2015 139.749 54.78%
2016 852.972 83.62%
2017 3.880.993 78.02%
2018 1.331.866 -191.4%
2019 2.188.809 39.15%
2020 2.725.988 19.71%
2021 4.598.550 40.72%
2022 4.312.084 -6.64%
2023 4.023.219 -7.18%

Organicell Regenerative Medicine, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.63
Net Income per Share
-0.99
Price to Earning Ratio
-2.78x
Price To Sales Ratio
4.38x
POCF Ratio
-9.09
PFCF Ratio
-8.99
Price to Book Ratio
-16.1
EV to Sales
4.15
EV Over EBITDA
-3.12
EV to Operating CashFlow
-8.61
EV to FreeCashFlow
-8.51
Earnings Yield
-0.36
FreeCashFlow Yield
-0.11
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
1.94
Graham NetNet
-0.29

Income Statement Metrics

Net Income per Share
-0.99
Income Quality
0.31
ROE
16.65
Return On Assets
-2.58
Return On Capital Employed
5.51
Net Income per EBT
1.03
EBT Per Ebit
1.03
Ebit per Revenue
-1.48
Effective Tax Rate
-0.07

Margins

Sales, General, & Administrative to Revenue
2.37
Research & Developement to Revenue
0.2
Stock Based Compensation to Revenue
0.7
Gross Profit Margin
0.89
Operating Profit Margin
-1.48
Pretax Profit Margin
-1.53
Net Profit Margin
-1.57

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.07
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.3
Free CashFlow per Share
-0.31
Capex to Operating CashFlow
0.01
Capex to Revenue
-0.01
Capex to Depreciation
-0.05
Return on Invested Capital
14.19
Return on Tangible Assets
-2.58
Days Sales Outstanding
2.37
Days Payables Outstanding
485.55
Days of Inventory on Hand
223.03
Receivables Turnover
154.05
Payables Turnover
0.75
Inventory Turnover
1.64
Capex per Share
-0

Balance Sheet

Cash per Share
0,24
Book Value per Share
-0,17
Tangible Book Value per Share
-0.17
Shareholders Equity per Share
-0.17
Interest Debt per Share
0.15
Debt to Equity
-0.56
Debt to Assets
0.25
Net Debt to EBITDA
0.18
Current Ratio
0.55
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-0.56
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
283861.5
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Organicell Regenerative Medicine, Inc. Dividends
Year Dividends Growth

Organicell Regenerative Medicine, Inc. Profile

About Organicell Regenerative Medicine, Inc.

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.

CEO
Dr. Harry L. Leider FACPE, M.B
Employee
20
Address
4045 Sheridan Avenue
Miami, 33140

Organicell Regenerative Medicine, Inc. Executives & BODs

Organicell Regenerative Medicine, Inc. Executives & BODs
# Name Age
1 Dr. Harry L. Leider FACPE, M.B.A., M.D., MBA
Chief Executive Officer & Director
70
2 Dr. Maria Ines Mitrani M.D.
Co-Founder, Vice President, Chief Science Officer & Director
70
3 Mr. Matthew Phillip Sinnreich
Pres & Acting Chief Executive Officer
70
4 Mr. Ryan Likes
Chief Operating Officer
70
5 Dr. Howard Lawrence Golub M.D., Ph.D.
Executive Vice President of Research & Development and Chief Science Officer
70
6 Mr. Albert Mitrani
Co-Founder, Sec., Treasurer & Executive Vice President of Sales
70
7 Dr. Harry L. Leider FACPE, M.B.A., M.D.
Chief Executive Officer & Director
70
8 Ms. Jackie Domenech
Vice President of Operation
70
9 Dr. Howard J. Golub M.D., Ph.D.
Executive Vice President & Chief Science Officer
70
10 Dr. Howard J. Golub M.D.
Executive Vice President & Chief Science Officer
70
11 Ms. Jill Swartz
Chief Product Officer
70
12 Dr. George C. Shapiro FACC, M.D.
Chief Medical Officer & Director
70
13 Mr. Ivan Santos
Biologics Manufacturing & Operations Mang.
70
14 Mr. David Aciego
Chief Information Officer
70

Organicell Regenerative Medicine, Inc. Competitors